Anti-coagulants

Anticoagulants (VTE & AF) Therapeutics Market is estimated to reach $17.2 billion by 2020

Posted on

The Anticoagulants (VTE & AF) Therapeutics Market was around $11.4 billion in 2015 and is estimated to reach $17.2 billion by 2020 growing at a CAGR of 8.59% from 2015 to 2020.

DelveInsight Report “Anticoagulants-Market Insights & Drugs Sales Forecast (VTE & AF) -2020” provides an overview of the Anticoagulants andAtrial Fibrillation and Venous Thromboembolism. The Report majorlyemphasizes on the global Anticoagulants market size and market size of theAnticoagulants by 7 Major Markets (United States, EU5 (France, Germany,Italy, Spain, UK) and Japan). The Report also covers the market size of Atrial

Fibrillation and Venous thromboembolism along with the market sales of the Key drugs by VTE and AF indications. It provides comprehensive review of Market Drivers, Market Barriers, Anticoagulants with coverage of detailed profile, Cost of therapy, Safety and Efficacy profiles and SWOT analysis.

The global anticoagulants market is categorized based on different classes like vitamin K reductase Inhibitor, heparin, low molecular weight heparin, Factor Xa Inhibitor and thrombin inhibitors.

Global AF market was $7.2 billion in 2015 and is expected to grow to $12.5 billion by 2020 with an compound annual growth rate (CAGR) of 11.62% where as Global VTE market was $4.2 billion in 2015 and is expected to grow to $4.75 billion by 2020 with a compound annual growth rate (CAGR) of 2.44%

With the recommendation of usage of novel oral anticoagulants (NOAC) by International guidelines in line with their established safety, efficacy and compliance, we expect decrease of warfarin use at a CAGR of negative 3.20% from 2015-2020 due to patient preferences in switching from warfarin to NOAC at a significant rate.  Novel Oral Anticoagulants (NOAC) will continue to be first-line oral agents, accounting for 70% of major-market sales in 2015.

Insights from recent studies clearly indicates that Physicians are relatively satisfied with the NOACs due to its efficacy and positive safety profiles without the need for anticoagulation monitoring and
dose frequencies. Conventional therapies (i.e., Warfarin) will remain entrenched as first-line therapies for most of the AF and VTE patients, followed by novel oral anticoagulants (NOAC) in the developing and underdeveloped countries due to the high cost of NOAC medications.

For more information on this report email us at info@delveInsight.com.

DelveInsight is a leading Business Consulting and Market Research Firm. DelveInsight helps the clients to find answers relevant to their business, facilitating decision-making; identify potential market opportunities, competitor assessments and business environmental assessment. In addition to this DelveInsight also deals in providing custom research services in coherence with interest area of the clients.

Advertisements

Global atrial fibrillation market is expected to grow to $12.5 billion by 2020 with and compound annual growth rate (CAGR) of 11.62%

Posted on

Global AF market was $7.2 billion in 2015 and expected to grow to $12.5 billion by 2020 with and compound annual growth rate (CAGR) of 11.62%. There are four NOACs which are indicated for the treatment of AF such as Xarelto, Eliquis, Pradaxa and Savaysa.

DelveInsight Atrial Fibrillation-Market Insights & Drugs Sales Forecast (AF) -2020 provides an overview of Atrial Fibrillation indication. The Report majorly emphasize on the global Anticoagulants market size and market size of the Anticoagulants by 7Major Markets (United States, EU5 (France, Germany, Italy, Spain, UK) and Japan). The Report also covers the market size of Atrial Fibrillation along with the market sales of the Key drugs by AF.  The Report provides comprehensive review of Market Drivers, Market barriers, Anticoagulants with coverage of detailed profile, Cost of therapy, Safety and Efficacy profiles and SWOT analysis.

With the new guideline by regulatory agencies has promoted the use of NOACs over warfarin. Atrial Fibrillation guidelines has also encouraged to use CHA2DS2-VASc score instead of the CHADS2 score for assessing stroke risk, which will cause a larger proportion of lower risk patients to receive anticoagulant treatment.

For more information email us @ info@delveinsight.com.

Global VTE market is expected to grow to $4.75 billion by 2020 with a compound annual growth rate (CAGR) of 2.44%

Posted on Updated on

Venous Thromboembolism- Market Insights & Drugs Sales Forecast (VTE) -2020: New Report by DelveInsight suggests that the Global VTE market was $4.2 billion in 2015 and expected to grow to $4.75 billion by 2020 with a compound annual growth rate (CAGR) of 2.44%.

DelveInsight Report “Venous Thromboembolism-Market Insights & Drugs Sales Forecast Thromboembolism indication. The Report majorly emphasize on the global market size venous thromboembolism. The Report provides Anticoagulants market size and Anticoagulants by 7 Major Markets (United States, EU5 (France, Germany, Italy, Spain, UK) and Japan) in Venous Thromboembolism indication.   The Report provides comprehensive review of Market Drivers, Market barriers, Anticoagulants with coverage of detailed profile, Cost of therapy, Safety and Efficacy profiles and SWOT analysis,

Coagulation is an important phenomenon of body to stop external bleeding but when clots are formed in blood vessels, it can be lethal. Blood clots in arteries can lead to heart attack and when formed in the blood vessels of brain can lead to stroke. Thus, anticoagulants are used to prevent the formation of blood clots in the body. Anticoagulants are proved to be a beneficial medication for the treatment of Atrial fibrillation, Deep Vein Thrombosis, Pulmonary Embolism and Stroke.  Globally the overall incidence for Venous Thromboembolism (VTE) is increasing at a higher rate. For VTE, there are approximately 1 million cases in the United States each year, many of which represent recurrent disease. The increasing epidemiology of venous thromboembolism is a key driver for the global anticoagulants market.   The global anticoagulants market is categorized based on different classes like vitamin K reductase Inhibitor, heparin, low molecular weight heparin, Factor Xa Inhibitor and thrombin inhibitors.

The VTE market is distributed among different class of anticoagulants including LMWH, NOACs and Warfarins. Once the patient diagnosed with the DVT or PE, two choices are provided ie warfarin with a parenteral anticoagulant for at least the first 5 days and until the international normalized ratio (INR) is therapeutic or novel oral anticoagulants (NOAC). Xarelto (rivaroxaban) and Eliquis (apixaban) are the preferred therapies due to less major bleeding.

For more information email us at info@delveinsight.com

Anticoagulants-Market Insights & Drugs Sales Forecast (VTE & AF)-2020- A DelveInsight Report

Posted on

According to DelveInsight researchers, the Anticoagulants (VTE & AF) Therapeutics Market was around $11.4 billion in 2015 and is estimated to reach $17.2 billion by 2020 growing at a CAGR of 8.59% from 2015 to 2020.

DelveInsight Report “Anticoagulants-Market Insights & Drugs Sales Forecast (VTE & AF) -2020” provides an overview of the Anticoagulants andAtrial Fibrillation and Venous Thromboembolism. The Report majorlyemphasizes on the global Anticoagulants market size and market size of theAnticoagulants by 7 Major Markets (United States, EU5 (France, Germany,Italy, Spain, UK) and Japan). The Report also covers the market size of Atrial

Fibrillation and Venous thromboembolism along with the market sales of the Key drugs by VTE and AF indications. It provides comprehensive review of Market Drivers, Market Barriers, Anticoagulants with coverage of detailed profile, Cost of therapy, Safety and Efficacy profiles and SWOT analysis.

The global anticoagulants market is categorized based on different classes like vitamin K reductase Inhibitor, heparin, low molecular weight heparin, Factor Xa Inhibitor and thrombin inhibitors.

Global AF market was $7.2 billion in 2015 and is expected to grow to $12.5 billion by 2020 with an compound annual growth rate (CAGR) of 11.62% where as Global VTE market was $4.2 billion in 2015 and is expected to grow to $4.75 billion by 2020 with a compound annual growth rate (CAGR) of 2.44%

With the recommendation of usage of novel oral anticoagulants (NOAC) by International guidelines in line with their established safety, efficacy and compliance, we expect decrease of warfarin use at a CAGR of negative 3.20% from 2015-2020 due to patient preferences in switching from warfarin to NOAC at a significant rate.  Novel Oral Anticoagulants (NOAC) will continue to be first-line oral agents, accounting for 70% of major-market sales in 2015.

Insights from recent studies clearly indicates that Physicians are relatively satisfied with the NOACs due to its efficacy and positive safety profiles without the need for anticoagulation monitoring and

dose frequencies. Conventional therapies (i.e., Warfarin) will remain entrenched as first-line therapies for most of the AF and VTE patients, followed by novel oral anticoagulants (NOAC) in the developing and underdeveloped countries due to the high cost of NOAC medications.

For more information on this report email us at info@delveInsight.com.

DelveInsight is a leading Business Consulting and Market Research Firm. DelveInsight helps the clients to find answers relevant to their business, facilitating decision-making; identify potential market opportunities, competitor assessments and business environmental assessment. In addition to this DelveInsight also deals in providing custom research services in coherence with interest area of the clients.

DelveInsight Business Research

+91-11-4568 9769

info@delveinsight.com

A Glimpse of the Anticoagulants Therapy Market & Major Players

Posted on Updated on

Anticoagulants

 

VTE therapeutics & Atrial Fibrillation market was worth USD 4 billion in 2014 and USD 7.86 billion respectively. The VTE therapeutic market is expected to reach USD 5.5 billion by 2018 with a Compound Annual Growth Rate (CAGR) of 8.29% and Atrial Fibrillation market will reach on its peak value USD 13.28 billion by 2018  with compound annual growth rate (CAGR) of 14%, according to DelveInsight Analysis.

 

Anticoagulants reduce blood clotting in an artery, a vein or the heart. Clots can block the blood flow to heart muscle leading to heart attack. They can also block blood flow to brain, leading to stroke. Anticoagulants are given to prevent blood from clotting or prevent existing clots from getting larger.

Warfarin and Heparin were the only available anticoagulants since decades but now, the choice of anticoagulants is broadened by the approval of new oral anticoagulants bu U.S. Food and Drug Administration. The new oral anticoagulants include Dabigatran, Rivaroxaban, Edoxaban, and Apixaban. These novel oral anticoagulants are expected to replace older anticoagulants with their ease of use and favourable pharmacodynamic profiles.

Dabigatran and Rivaroxaban were the highest selling drugs in 2014 with the revenue generated ~1800 million and ~1700 million respectively. Dabigatran was the first oral direct thrombin inhibitor approved by U.S. FDA and Rivaroxaban was the first oral direct coagulation factor Xa inhibitor approved by U.S. FDA. The patent for Dabigatran is going to expire soon (in 2017) thus making way for generic drug in the market. Edoxaban is the newly approved (January 2015) factor Xa inhibitor for the prevention of ischemic stroke and systemic embolism in patients with non-valvular atrial fibrillation (NVAF) and the treatment and recurrence prevention of venous thromboembolism (VTE).

Sales of major players in the market

Sales of major players in the market

Despite novel anticoagulants are seen as replacements for heparin and warfarin, there are some adverse hemorrhagic events reported. Absence of any approved antidotes for oral anticoagulants limit their use. Though there are 3 antidotes in clinical development which can reverse the effects in case of major bleeding. These antidotes are 1.5 years away from being clinically available.

Since the patient compliance increases with the orally available drugs, the companies are focusing on developing such anticoagulants. The drugs in pipeline are mostly thrombin inhibitors or Factor Xa inhibitors unlike traditionally used warfarin which was Vitamin K reductase inhibitor.

Anticoagulants are prescribed for number of diseases such as Heart attack, stroke, deep venous thromboembolism, pulmonary embolism, Atrial fibrillation, Unstable angina, or for the prevention of Venous thromboembolism (VTE) after major orthopedic surgery. With such a wide usage, one must be familiar with anticoagulants, their pharmacological properties, pharmacodynamics, dosing, monitoring and toxicity.

Written by Rashi Aggarwal, Associate Analyst at DelveInsight

Report: Anticoagulants-Competitive Landscape, Market & Pipeline Analysis, Forecasted Market Size 2015-2018

Give your views in the comment section and for more information on this Report and Sample Pages mail us at info@delveinsight.com

Anticoagulants Market A Big Boom

Posted on Updated on

Analyze Anticoagulants Market with DelveInsight

Anticoagulants are drugs that are given to prevent blood from clotting or prevent existing clots from getting larger. They can keep harmful clots from forming in heart, veins or arteries. Clots can block blood flow and cause a heart attack or stroke. Until recently, the only available oral anticoagulants were the vitamin K antagonists, such as warfarin which is an Injectable solution. In the past few years, however, the landscape has changed with the introduction of new oral anticoagulants that specifically target either factor Xa or thrombin. Rivaroxaban, dabigatran and apixaban, the oral factor Xa inhibitors, are active compounds with an oral bioavailability of more than 50%. The new oral anticoagulants have several advantages over warfarin, including pharmacology, laboratory monitoring, class effects and differentiating effects.

SasaqaSasMost drugs are recommended for Deep Vein thromboembolism (DVT) and pulmonary embolisms (PE) while the least being heparin-induced thrombocytopenia, thrombocytopenia, Peripheral vascular occlusion, Non-Q wave myocardial infarction, and disseminated intravascular coagulation. Currently there are 10 drugs and 9 drugs which are used for PE and DVT respectively.

mARKETED

DelveInsight- Anti-coagulant Report, “Anticoagulants-Competitive Landscape, Market & Pipeline Analysis, Forecasted Market Size 2015-2018”.

This DelveInsight report provides a thorough overview of these new oral anticoagulants, their approved indications, drug profiles, pharmacokinetic parameters and market growth, historical sales and forecasted sales of each molecule till 2018. The Report also provides the pipeline information and their drug profiles giving therapeutic analysis by route, mechanism of action and molecule type. The Report has also highlighted the two prevalent indications, Venous Thromboembolism and Atrial Fibrillation, its epidemiology segmented by geography and their current and future market. The Report has also given analysis on the basis of SWOT analysis.

For more information on this report and Sample Pages, mail us at info@delveinsight.com